SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services

Lund, Sweden and Copenhagen, Denmark – November 11, 2024

SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership with the goal to offer
enhanced hit and lead identification services based on their complementary technology platforms. By
combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, the
companies will enhance their drug discovery services by offering expedited hit identification and lead
generation.

Vipergen’s high-fidelity DNA encoded library (DEL) screening technologies enable the identification of novel
hit compounds by screening 500+ million drug-like molecules in a single tube or in living cells. Structural
information involving detailed information about binding sites and binding poses of identified compounds
can rapidly be generated by utilizing SARomics Biostructures structural biology capabilities. This combined
information will greatly enhance and accelerate subsequent lead generation of identified hit compounds.

“The collaboration with Vipergen will leverage hit identification and lead generation towards challenging
targets and accelerate the discovery of novel therapies” commented Björn Walse, Chief Executive Officer of
SARomics.

“Vipergen is pleased to enter into a strategic collaboration with SARomics, a recognized leader in the
structural biology field whose high-quality proteins meet all requirements for successful DEL screens,” said
Nils Hansen, Chief Executive Officer of Vipergen. “We are excited to leverage our collaboration with
SARomics to facilitate even better outcomes for Vipergen’s drug discovery clients.”

About SARomics Biostructures AB
SARomics Biostructures, Lund, Sweden provides structural biology and structure-based drug design services
to biotech, pharmaceutical, and academic organizations. SARomics has built a global reputation for its
structural biology skills and is currently supporting clients in North America, Europe and Japan to pursue
their drug discovery objectives. For more information, please visit www.saromics.com.

About Vipergen ApS
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded
library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell.
Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery
partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical
companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder
Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms,
please visit www.vipergen.com.

For additional information please contact:

Dr. Björn Walse, CEO
SARomics Biostructures AB
sales@saromics.com

Dr. Nils Jakob Vest Hansen, CEO
Vipergen ApS
info@vipergen.com